Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:

• Wells Fargo 21^st Annual Healthcare Conference. Fireside chat on Wednesday, September 9, 2026 at 12:45 PM ET in Boston
  
  
• Cantor Global Healthcare Conference 2026. Fireside chat on Thursday, September 10, 2026 at 8:35 AM ET in New York
  
  
• Morgan Stanley 24^th Annual Global Healthcare Conference. Fireside chat on Tuesday, September 15, 2026 at 10:45 AM ET in New York

The webcasts can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)  

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

Contact: Neurocrine Biosciences, Inc.
Tony Jewell (Media)
858-617-7578
[email protected]

Todd Tushla (Investors)
858-617-7143
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-september-302867834.html

SOURCE Neurocrine Biosciences, Inc.